Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
Express Scripts
QuintilesIMS
Moodys
Farmers Insurance
Chinese Patent Office
Merck
McKinsey
Julphar

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,532,415

« Back to Dashboard

Summary for Patent: 5,532,415
Title: R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
Abstract:The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
Inventor(s): Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL)
Assignee: Teva Pharmaceutical Industries Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:08/411,398
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 5,532,415

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,532,415

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel92952Jan 03, 1990

International Patents Family Members for US Patent 5,532,415

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 106860 ➤ Subscribe
Austria 284208 ➤ Subscribe
Australia 1253495 ➤ Subscribe
Australia 5872396 ➤ Subscribe
Australia 630772 ➤ Subscribe
Australia 6772490 ➤ Subscribe
Australia 699090 ➤ Subscribe
Brazil 9608733 ➤ Subscribe
Canada 2031714 ➤ Subscribe
Canada 2174449 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Novartis
Queensland Health
US Department of Justice
Cipla
Dow
McKesson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot